Oxygen therapy could tame severe colitis Flare-Ups
NCT ID NCT07257588
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard steroid drugs helps people with severe ulcerative colitis get better faster. About 44 adults with acute severe colitis will be randomly assigned to receive either standard treatment alone or standard treatment plus hyperbaric oxygen. The goal is to see if the oxygen therapy improves symptoms and reduces inflammation in the colon.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hyperbaric oxygen therapy
- What this could lead to
- If it works, this could provide a new, non-drug option to help control severe flare-ups of ulcerative colitis.
- What could go wrong
- This is a small, early-stage study with only 44 participants, so results may not apply to everyone. Hyperbaric oxygen can cause ear or sinus discomfort in some people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 44 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Dec 2025
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * According to the diagnostic criteria for ulcerative colitis in the 2018 national consensus opinion on the diagnosis and treatment of inflammatory bowel disease, it was confirmed as ulcerative colitis; * According to the Truelove-witts standard, it was diagnosed as acute severe ulcerative colitis: the frequency of bloody stools per day is 6 times or more, and at the same time, one of the following systemic toxic manifestations is present: heart rate of 90 bpm, body temperature greater than 37.8℃, hemoglobin less than 105g/L, and erythrocyte sedimentation rate greater than 30mm/h; * Age ≥ 18 years old; * Patients who can and are willing to comply with the research protocol can provide a signed and dated written informed consent form. Exclusion Criteria: * Patients who may require immediate surgical treatment; * Pregnant or lactating mothers; * Patients with a score of ≥6 years old (TMM30/40/50) and \<6 points in the measurement of the Eustachian tube; * Patients with a lung bulla larger than 2 cm at the lung apex or near the pleura in the chest plain scan; * Patients with severe liver or kidney dysfunction, heart failure or other serious systemic diseases; * Any situation that hinders the completion of the study or interferes with the analysis of the research results, including a history of drug or alcohol abuse, a smoker who has not quit, patients with mental illness or poor compliance, those with clear immune system (including HIV infection), blood system or tumor-related diseases; * Patients who have withdrawn their informed consent; * Patients who have participated in other clinical trials within 3 months before screening.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Xijing hospital of digestive diseases
Xi'an, Shaanxi, 710032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Can a cheap Anti-Inflammatory drug calm ulcerative colitis?
- Which IBD therapy works best for kids? researchers compare two approaches
- Can trained peer mentors ease the mental toll of IBD?
- Can a new infusion drug calm ulcerative colitis?
- A breath test for gut disease? researchers hunt for invisible clues